KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,352 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,352 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now directly owns 250,800 shares in the company, valued at $3,057,252. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ KALV traded down $0.66 on Tuesday, reaching $11.21. 556,002 shares of the company traded hands, compared to its average volume of 501,665. The stock has a market capitalization of $484.50 million, a PE ratio of -3.30 and a beta of 0.89. The company has a 50 day moving average of $13.16 and a 200 day moving average of $12.39. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.21 and a fifty-two week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. As a group, research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.57 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Campbell & CO Investment Adviser LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth about $507,000. Frazier Life Sciences Management L.P. boosted its holdings in KalVista Pharmaceuticals by 11.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after acquiring an additional 383,435 shares during the period. China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 101.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 4,043 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of KalVista Pharmaceuticals by 94.5% during the first quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 8,750 shares during the period. Finally, ClariVest Asset Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the first quarter worth $659,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.